Monday, February 16, 2026 2/16/2026

Mitochondrial regulation of calcium homeostasis and cell death in muscular dystrophy

Award Number: K99AR078253
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 09/01/2021
PERIOD OF PERFORMANCE END DATE: 05/31/2024

Group Awards By:

View Award Description

Mitochondrial regulation of calcium homeostasis and cell death in muscular dystrophy - ABSTRACT PROJECT SUMMARY Muscular Dystrophy (MD) is a family of genetic disorders characterized by progressive muscle wasting, loss of muscle function, and premature death. MD pathology is driven by sarcolemma instability resulting in membrane rupture, necrosis, and myofiber death. Research has demonstrated that MD myofibers have increased cellular Ca2+ levels and that mitochondrial membrane permeability pore (MPTP) dependent myofiber death contributes to MD. There is evidence that MD myofiber mitochondria have elevated Ca2+ levels, but isolated MD mitochondria also have reduced Ca2+ uptake rates and increased expression of MCUb, a negative regulator of Ca2+ uptake. In the heart limiting mitochondrial Ca2+ uptake protects from MPTP-dependent cell death, while genetically promoting Ca2+ overload leads to increased MPTP-activation and cell death. We will therefore test the role of mitochondrial Ca2+ homeostasis in MD (Aim #1). We will disrupt the main mitochondrial Ca2+ efflux mechanism by deleting the myofiber mitochondrial Na+/Ca2+ exchanger (Nclx) in the Mdx model of MD to test the hypothesis that Ca2+ overload promotes MPTP-dependent myofiber death and pathology in MD. We will also disrupt the acute mitochondrial Ca2+ uptake mechanism by deleting the mitochondrial Ca2+ uniporter (Mcu) in myofbers in the Mdx model of MD to test the hypothesis that inhibiting Ca2+ uptake will reduce MPTP-dependent myofiber death pathology in MD. We will delete myofiber Mcub in the Mdx model of MD to test the hypothesis that increased MCUb expression in MD myofibers is protective in MD disease. To better understand the role of MPTP in MD disease we will directly target the MPTP genetically. We have recently demonstrated that adenine nucleotide translocator (ANT) proteins represent one of at least two protein species that comprise the MPTP. It has recently been observed that isolated MD myofiber mitochondria have increased sensitivity to MPTP- activation as well as a specific increase in ANT2 expression. We will therefore test the role of ANT-dependent MPTP activation in MD (Aim #2). We will study Ant1 knockout mice in the Sgcd-/- model of MD, which lack the main muscle ANT isoform, to test the hypothesis that ANT-dependent MPTP (MPTPANT) contributes to MD pathology. We will delete myofiber Ant2 in the Sgcd-/- model of MD to test the hypothesis that ANT2 upreglation in MD mitochondria specifically promotes MPTP activation and pathology in MD. Additionally, we will generate mice lacking all murine isoforms of ANT in the Sgcd-/- model of MD to measure the total contribution of MPTPANT to MD. Since we have demonstrated that inhibition of cyclophilin D (CypD) in the context of total ANT knockout is sufficient to completely inhibit MPTP, we will treat Sgcd-/- mice lacking all ANT isoforms with the CypD inhibitor Debio-025 to test what proportion of total myofiber death and MD pathology is dependent on MPTP-activation. This research will be the first test of the role of mitochondrial Ca2+ in MD pathobiology and the first study of the ANT model of MPTP in a physiological system. This research may uncover novel strategies to treat MD, for which there is currently no cure or effective treatment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	CHILDRENS HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	10/11/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	CHILDRENS HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	5/31/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	CHILDRENS HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	6/26/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $90,720 )
2022	2022	CHILDREN'S HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	8/16/2022	NON-COMPETING CONTINUATION	$90,720
														Subtotal = $90,720

Issue Date FY: 2021 ( Subtotal = $90,720 )
2021	2021	CHILDREN'S HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	8/25/2021	NEW	$90,720
														Subtotal = $90,720

Grand Total All Awards = $181,440

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mitochondrial regulation of calcium homeostasis and cell death in muscular dystrophy

Award Number: K99AR078253

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 09/01/2021

PERIOD OF PERFORMANCE END DATE: 05/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer